Skip to main navigation menu Skip to main content Skip to site footer

Vol. 10 No. 12 (2023)
International Multidisciplinary Journal for Research & Development

Articles

CRITERIAS FOR TREATMENT OF ARTERIAL HYPERTENSION AND CORONARY HEART DISEASES

Published 2023-12-17

  • Isfandiyor Abduraximovich Muminov

Isfandiyor Abduraximovich Muminov
Assistant of the department of Inner diseases Andijan State Medical Institute, Andijan city, Uzbekistan

Abstract

The literature review is devoted to the features of the course, the choice of drugs for the treatment ischemic heart disease in combination with arterial hypertension.

Keywords

Ischemic heart disease, arterial hypertension, therapy.

DOWNLOAD PDF CERTIFICATE

References

  1. All-Russian Scientific Society of Cardiology (VNOK). National guidelines for diagnosis and treatment of arterial hypertension. M 2004.
  2. Committee of experts of VNOK. Diagnosis and treatment of stable angina pectoris. Russian recommendations. Cardiovascular Therapy and Prevention (Appendix) 2004.
  3. Syrkin A.L. Treatment of stable angina pectoris. Consilium medicum. 2000; 2:470-477.
  4. ASCOT study investigators, 2005. http://www.ascotstudy.org/home. htm.
  5. Armstrong P.W. Stable ischemic syndromes. In: Textbook of cardiovascular medicine. Ed. E.J. Topol. Philadelphia PA: Lippincott Williams & Wilkins-Raven 1998;333- 364.
  6. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: INSIGHT. Lancet 2000;356:366-372.
  7. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high pressure: The JNC 7 report. JAMA 2003; 289:2560–2572.
  8. Collins R., Peto R., MacMahon S. et al. Blood pressure, stroke, and coronary heart disease. Part 2: Shortterm reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
  9. Dzau V., Bernstein K., Celermaier D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88:Suppl L:L1-L20.
  10. Grundy S.M., Cleeman A., Merz C.N.B. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239.
  11. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
  12. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-365.
  13. Hansson L., Lindholm L., Ekbom T. et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756.
  14. Julius S., Kjeldsen S. E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomized trial. Lancet 2004;363:2021-2031.
  15. La Rosa J.C., Grundy S.M., Waters D.D. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435.
  16. Neaton J.D., Wentworth D. for the Multiple Risk Factor Intervention Trial Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men. Arch Intern Med 1992;152:56-64.
  17. Nissen S.E., Tuscu E.M., Libby P. et al. effect of antihypertensive agents on cardiovascular events in patients with coronary artery disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2226.
  18. PEACE Trial investigators. Angiotensinconverting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
  19. Pepine C., Handberg E.M., Cooper-deHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816.
  20. Pitt B., O'Neill B., Feldman R. et al. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-1063.
  21. Rosendorff C. Treatment of hypertension patients with ischemic heart disease. In: Hypertension Primer: The essentials of high blood pressure: basic science, population science and clinical management. Eds. J.L.Jr. Izzo, H.R. black. Philadelphia PA: Lippincott Williams & Wilkins 2003;456-459.
  22. Sever P.S., Dahlof B., Poulter N.R. et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-1158.

Downloads

Download data is not yet available.